Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china

Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china

10.2147/CMAR.S219722

Saved in:

Bibliographic Details
Main Authors:	You, R., Liu, J., Wu, D.B.-C., Qian, X., Lyu, B., Zhang, Y., Luo, N.
Other Authors:	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
Format:	Article
Published:	Dove Medical Press Ltd 2021
Subjects:	Afatinib Economic analysis EGER mutation testing Incremental cost-effectiveness ratio NSCLC
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/210062
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
by: Chang, Gee-Chen, et al.
Published: (2022)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
by: Tan, P.-T, et al.
Published: (2020)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, S, et al.
Published: (2020)

Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy
by: Limviphuvadh, Vachiranee, et al.
Published: (2018)

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
by: Salto-Tellez, M., et al.
Published: (2014)

CHARACTERIZING CISPLATIN-RESISTANT NSCLC CELLS AND IDENTIFYING TRAIL AS A POTENTIAL SECOND-LINE THERAPY IN REFRACTORY CANCER CELLS
by: SEAH BEE KEE SERENA
Published: (2013)

Cost-effectiveness of different human papillomavirus vaccines in Singapore
by: Lee, V.J., et al.
Published: (2014)

Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with egfr tki and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells
by: Dyrstad, Sissel E., et al.
Published: (2022)

Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
by: Tan, E.-H., et al.
Published: (2014)

The IκB kinase inhibitor ACHP targets the STAT3 signaling pathway in human non-small cell lung carcinoma cells
by: Lee, J.H., et al.
Published: (2021)

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy
by: Soo, R.A., et al.
Published: (2014)

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
by: Chin, T.-M., et al.
Published: (2021)

TARGETING THE PIK3 PATHWAY IN NON-SMALL CELL LUNG CANCER
by: DANIEL TAN SHAO WENG
Published: (2017)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

REGULATION OF AMPK ACTIVATION AND ITS ROLE IN CELL DEATH INDUCED BY GLUCOSE STARVATION IN LKB1-MUTANT HUMAN LUNG CANCER CELLS
by: REN YI
Published: (2019)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2014)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2011)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
by: Costa D.B., et al.
Published: (2018)

Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations
by: Haaland, B., et al.
Published: (2016)

Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity
by: Zhang, X., et al.
Published: (2021)

Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix
by: Alfonso Dueñas-González, et al.
Published: (2018)

A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians
by: Peng, S., et al.
Published: (2021)

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma
by: Lee, S.-C., et al.
Published: (2012)

Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer
by: Song, L., et al.
Published: (2021)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer
by: Ali, A, et al.
Published: (2020)

Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study
by: Keunchil Park, et al.
Published: (2018)

Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study
by: Keunchil Park, et al.
Published: (2018)

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
by: Nokihara, H, et al.
Published: (2022)

Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer
by: Huang, Yiqing, et al.
Published: (2022)

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma
by: Chalyut Charoentum, et al.
Published: (2018)

The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases
by: Pang, B., et al.
Published: (2014)

Impact of smoking and brain metastasis on outcomes of advanced EGFR mutation lung adenocarcinoma patients treated with first line epidermal growth factor receptor tyrosine kinase inhibitors
by: Jain A., et al.
Published: (2020)

Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis
by: Zhu, Viola W., et al.
Published: (2022)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
by: Wang D.D., et al.
Published: (2019)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

Incremental self-growing neural networks with the changing environment
by: Su, L., et al.
Published: (2014)

Semi-supervised new slot discovery with incremental clustering
by: WU, Yuxia, et al.
Published: (2022)